(BFRG) Bullfrog AI Holdings - Ratings and Ratios

Bullfrog AI Holdings, Inc. is a digital biopharmaceutical company leveraging artificial intelligence (AI) and machine learning (ML) to analyze medical and healthcare datasets. The companys flagship platform, bfLEAP, is designed to optimize preclinical and clinical data analysis, accelerating drug discovery and development. Bullfrog AI has established strategic licensing agreements with academic institutions, including George Washington University for siRNA targeting Beta2-spectrin to treat hepatocellular carcinoma, obesity, and liver diseases, and Johns Hopkins University for a Mebendazole formulation targeting glioblastoma and other cancers. Founded in 2017 and headquartered in Gaithersburg, Maryland, the company operates at the intersection of AI-driven analytics and precision medicine.

From a technical standpoint, BFRG has shown recent price weakness, trading below its 20-day, 50-day, and 200-day moving averages. The stocks average true range (ATR) of 0.41 indicates moderate volatility. The 20-day average volume of 1.93 million shares reflects relatively thin liquidity, which can amplify price movements. The current price of $1.80 is below the 20-day SMA of $2.73, suggesting near-term bearish momentum.

Fundamentally, Bullfrog AIs market cap of $22.83 million reflects its early-stage positioning in the AI-driven biopharma space. The price-to-book (P/B) ratio of 5.66 indicates a premium valuation relative to book value, likely driven by expectations for future growth. The price-to-sales (P/S) ratio of 530.83 is elevated, signaling investor confidence in the companys long-term revenue potential despite current losses.